Clinical Trial: A Study to Assess Safety and Efficacy of Risankizumab Using a New Formulation in Participants With Moderate to Severe Plaque Psoriasis

U.S., March 22 -- ClinicalTrials.gov registry received information related to the study (NCT03875482) titled 'A Study to Assess Safety and Efficacy of Risankizumab Using a New Formulation in Participants With Moderate to Severe Plaque Psoriasis' on March 13.

Brief Summary: The objective of this study is to evaluate efficacy and safety of risankizumab using a new formulation compared with placebo for treatment of moderate to severe plaque psoriasis.

Study Type: Interventional

Condition: Psoriasis

Intervention: * Drug: Risankizumab

Risankizumab is administered as subcutaneous (SC) injection

Other Names:

ABBV-066

BI 655066

* Drug: Placebo

Placebo for risankizumab is administered as subcutaneous (SC) injection

Recruitment Status: Not...